Clinical Trials Browser

Phase 1 × Osteosarcoma × Standard of Care × Clear all

NCT03628209 2026-02-05

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Phase 1 Active not recruiting

Sarcoma, Osteosarcoma